JP2004529161A - 縮合複素環式化合物 - Google Patents

縮合複素環式化合物 Download PDF

Info

Publication number
JP2004529161A
JP2004529161A JP2002586869A JP2002586869A JP2004529161A JP 2004529161 A JP2004529161 A JP 2004529161A JP 2002586869 A JP2002586869 A JP 2002586869A JP 2002586869 A JP2002586869 A JP 2002586869A JP 2004529161 A JP2004529161 A JP 2004529161A
Authority
JP
Japan
Prior art keywords
alkyl
aryl
hydrogen
group
arylalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002586869A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004529161A5 (enExample
Inventor
チェン，シャオキー
ダイ，カン
ファン，ピンチェン
ホワン，シュウギ
リ，レピン
ミハリク，ジェフリー，トーマス
Original Assignee
トゥラリック インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トゥラリック インコーポレイテッド filed Critical トゥラリック インコーポレイテッド
Publication of JP2004529161A publication Critical patent/JP2004529161A/ja
Publication of JP2004529161A5 publication Critical patent/JP2004529161A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2002586869A 2001-05-04 2002-05-03 縮合複素環式化合物 Pending JP2004529161A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28866501P 2001-05-04 2001-05-04
PCT/US2002/013856 WO2002089729A2 (en) 2001-05-04 2002-05-03 Fused heterocyclic compounds

Publications (2)

Publication Number Publication Date
JP2004529161A true JP2004529161A (ja) 2004-09-24
JP2004529161A5 JP2004529161A5 (enExample) 2005-12-22

Family

ID=23108101

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002586869A Pending JP2004529161A (ja) 2001-05-04 2002-05-03 縮合複素環式化合物

Country Status (9)

Country Link
US (1) US6858619B2 (enExample)
EP (1) EP1392298B1 (enExample)
JP (1) JP2004529161A (enExample)
AT (1) ATE422887T1 (enExample)
AU (1) AU2002305323A1 (enExample)
CA (1) CA2446351A1 (enExample)
DE (1) DE60231202D1 (enExample)
ES (1) ES2319619T3 (enExample)
WO (1) WO2002089729A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6809104B2 (en) 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
US20070135425A1 (en) * 2001-05-04 2007-06-14 Amgen Inc. Fused heterocyclic compounds
ES2319619T3 (es) 2001-05-04 2009-05-11 Amgen Inc. Compuestos heterociclicos condensados.
AU2002352878B2 (en) * 2001-11-27 2007-11-22 Merck Sharp & Dohme Corp. 2-Aminoquinoline compounds
EP1451156A4 (en) * 2001-11-27 2005-05-25 Merck & Co Inc 4-AMINOCHINOLINVERBINDUNGEN
WO2003060475A2 (en) 2002-01-10 2003-07-24 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole analogues
WO2003059289A2 (en) 2002-01-10 2003-07-24 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
MXPA05004739A (es) * 2002-11-06 2005-08-02 Tularik Inc Compuestos heterociclicos fusionados.
AU2004209505B2 (en) * 2003-02-10 2009-07-23 Banyu Pharmaceutical Co., Ltd. Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
US7319108B2 (en) 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
US7241787B2 (en) 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
DE102004039789A1 (de) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP4870163B2 (ja) 2005-09-30 2012-02-08 エフ．ホフマン−ラ ロシュ アーゲー Ｍｃｈ受容体アンタゴニストとしてのインダン誘導体
CA2636617A1 (en) 2006-02-15 2007-08-23 Lothar Schwink Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
UY32443A (es) 2009-02-13 2010-09-30 Sanofi Aventis Nuevos tetrahidronaftalenos, procesos para su preparación y uso de los mismos como medicamento.
AR075401A1 (es) 2009-02-13 2011-03-30 Sanofi Aventis Indanos sustituidos, procesos para su preparacion y uso de los mismos como un medicamento
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011044134A1 (en) * 2009-10-05 2011-04-14 Albany Molecular Research, Inc. Epiminocycloalkyl(b)indole derivatives as serotonin sub-type 6 (5-ht6) modulators and uses thereof
AU2012207335A1 (en) 2011-01-19 2013-07-25 Albany Molecular Research, Inc. Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-HT6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US20150051220A1 (en) * 2012-03-16 2015-02-19 Glucox Biotech Ab Compounds for use in therapy
JP6274384B2 (ja) * 2012-04-27 2018-02-07 Nok株式会社 メタルガスケット及びその製造方法
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2906654B2 (ja) 1989-11-28 1999-06-21 東レ株式会社 免疫抑制剤及びその製造方法
ES2173866T3 (es) * 1991-07-05 2002-11-01 Glaxosmithkline Spa Derivados de hidroisoquinolina.
FI942499A7 (fi) 1992-09-29 1994-07-27 Toray Industries Indolijohdannainen, menetelmä sen valmistamiseksi ja sen lääkekäyttö
US5464841A (en) 1993-11-08 1995-11-07 Univ Minnesota Use of delta opioid receptor antagonists to treat immunoregulatory disorders
US5578725A (en) 1995-01-30 1996-11-26 Regents Of The University Of Minnesota Delta opioid receptor antagonists
ES2217533T3 (es) 1997-01-16 2004-11-01 Toray Industries, Inc. Derivados de indolomorfinano y medicamentos/preventivos para transtornos cerebrales.
DE69934504T2 (de) 1998-10-07 2007-10-04 Sharp K.K. Halbleiterlaser
GB9822158D0 (en) 1998-10-09 1998-12-02 Nycomed Imaging As Compositions
AU2573900A (en) 1999-02-19 2000-09-04 Takeda Chemical Industries Ltd. Novel g protein-coupled receptor protein and dna thereof
WO2001007606A1 (en) 1999-07-27 2001-02-01 Smithkline Beecham Plc Axor21, a g-protein coupled receptor
JP2001226269A (ja) 2000-02-18 2001-08-21 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
EP1283199A4 (en) 2000-05-16 2003-12-17 Takeda Chemical Industries Ltd MELANINE CONCENTRATING HORMONE ANTAGONISTS
EP1299362A4 (en) 2000-07-05 2004-11-03 Synaptic Pharma Corp SELECTIVE RECEPTOR ANTAGONISTS OF MELANINE CONCENTRATING HORMON-1 (MCH1) AND THEIR USE
WO2002002744A2 (en) 2000-07-05 2002-01-10 Synaptic Pharmaceutical Corporation Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof
US7273710B2 (en) 2000-07-05 2007-09-25 Takeda Pharmaceutical Company Limited Method for screening MCH receptor antagonist/agonist
WO2002004433A2 (en) 2000-07-06 2002-01-17 Neurogen Corporation Melanin concentrating hormone receptor ligands
WO2002032897A1 (en) 2000-10-20 2002-04-25 Pfizer Products Inc. Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists
US20030022891A1 (en) 2000-12-01 2003-01-30 Anandan Palani MCH antagonists and their use in the treatment of obesity
HUP0302582A2 (hu) 2000-12-22 2003-12-29 Schering Corp. Piperidin MCH antagonisták, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk elhízás kezelésére
US6900329B2 (en) 2001-03-21 2005-05-31 Schering Corporation MCH antagonists and their use in the treatment of obesity
AU2002247367B2 (en) 2001-03-21 2005-10-27 Pharmacopeia Drug Discovery, Inc. Aryl and biaryl compounds having MCH modulatory activity
CA2443672C (en) 2001-04-12 2011-03-29 Pharmacopeia, Inc. Aryl and biaryl piperidines used as mch antagonists
ES2319619T3 (es) 2001-05-04 2009-05-11 Amgen Inc. Compuestos heterociclicos condensados.
BR0209932A (pt) 2001-05-22 2004-10-13 Neurogen Corp Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, preparação farmacêutica embalada, métodos para modular ligação de mch a um receptor de mch e de mvc, para alterar a atividade de transdução de sinal de um receptor de mch em uma célula, para tratar uma doença ou distúrbio associado com a ativação de receptor de mch patogênico obesidade e para determinar a presença ou ausência de receptor de mch em uma amostra, e, uso de um composto

Also Published As

Publication number Publication date
WO2002089729A3 (en) 2003-04-03
CA2446351A1 (en) 2002-11-14
EP1392298B1 (en) 2009-02-18
WO2002089729A2 (en) 2002-11-14
AU2002305323A1 (en) 2002-11-18
ES2319619T3 (es) 2009-05-11
ATE422887T1 (de) 2009-03-15
EP1392298A2 (en) 2004-03-03
US20030023085A1 (en) 2003-01-30
US6858619B2 (en) 2005-02-22
EP1392298A4 (en) 2005-05-25
DE60231202D1 (de) 2009-04-02

Similar Documents

Publication Publication Date Title
EP1392298B1 (en) Fused heterocyclic compounds
US7045527B2 (en) Piperidine derivatives
TW322478B (enExample)
Sniecikowska et al. From receptor selectivity to functional selectivity: the rise of biased agonism in 5-HT1A receptor drug discovery
KR20180086247A (ko) 키나제 조절을 위한 화합물 및 방법과 이들에 대한 징후
JP2010510987A (ja) ヘテロアリールアミド誘導体
KR20070043998A (ko) 히스타민 ｈ3 수용체 리간드로서의 피페리딘 유도체
US20080058365A1 (en) Fused heterocyclic compounds
CN102170883A (zh) 可用作蛋白激酶抑制剂的化合物
CN106715435A (zh) 作为nr2b nmda受体拮抗剂的吡咯并嘧啶衍生物
JP2021520340A (ja) 化合物およびｐｄｅ４活性剤としてのそれらの使用
US6809104B2 (en) Fused heterocyclic compounds
JP2000516957A (ja) 置換されている１，２，３，４―テトラヒドロ―２―ジベンゾフランアミン類および２―アミノシクロヘプタ［ｂ］ベンゾフラン類
Zhang et al. Design, synthesis and SAR of novel 7-azaindole derivatives as potential Erk5 kinase inhibitor with anticancer activity
US20070135425A1 (en) Fused heterocyclic compounds
Modica et al. Serotonin 5-HT3 and 5-HT4 ligands: an update of medicinal chemistry research in the last few years
US7030122B2 (en) 1,4-disubstituted piperazine ligands for neurotransmitter receptors
Fulton Challenges in the Discovery and Optimization of MGLU2/4 Heterodimer Positive Allosteric Modulators and Total Synthesis of Epi-and Pericoannosin A

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090811